Literature DB >> 18475249

In vitro receptor binding assays: general methods and considerations.

H M Bigott-Hennkens1, S Dannoon, M R Lewis, S S Jurisson.   

Abstract

The development of receptor-targeting radiopharmaceuticals commonly involves the use of peptides, antibodies or small molecules. Resulting from the numerous modifications that can be made to these basic targeting agents, research in this field often generates a series of compounds as potential ligands for in vivo investigation. However, measuring each variant of a series in vivo can be both costly and time-consuming. Therefore, a number of in vitro assays, to study interactions between the targeted receptor and the ligands of interest, are frequently used to quickly and inexpensively narrow the field and identify a lead compound(s) for further investigation. For example, in saturation binding studies, the amount of radioligand required to saturate the receptors is measured and analyzed to determine the radioligand equilibrium dissociation constant (Kd), a useful gauge of the receptor binding affinity of a radioligand. In competitive binding experiments, a ligand of interest competes for available receptor sites with a standard radioligand of known high receptor affinity. Competition data are analyzed to yield another indicator of receptor affinity, called an IC50 value, which can be used to rank the relative receptor binding affinities for a series of ligands. In internalization and efflux studies, the rate and extent of receptor-mediated radioligand taken into and subsequently released from cells is measured, providing insight into cellular uptake and retention of the radioligand. Individually or taken together, these in vitro receptor binding assays are useful tools in radiopharmaceutical development.

Mesh:

Substances:

Year:  2008        PMID: 18475249

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  13 in total

1.  Displacement Binding Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells.

Authors:  Maria Grazia Cascio; Pietro Marini; Roger G Pertwee
Journal:  Methods Mol Biol       Date:  2023

Review 2.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

3.  Determining target engagement in living systems.

Authors:  Gabriel M Simon; Micah J Niphakis; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2013-04       Impact factor: 15.040

Review 4.  Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management.

Authors:  Fang Fang; Hongwei Sun; Zuowei Wang; Ming Ren; Joseph R Calabrese; Keming Gao
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

5.  Optimization binding studies of opioid receptors, saturation and competition, using [3H]-DAMGO.

Authors:  Mona Khoramjouy; Fatemeh Ahmadi; Mehrdad Faizi; Soraya Shahhosseini
Journal:  Pharmacol Rep       Date:  2021-04-19       Impact factor: 3.024

6.  Binding Interactions of Keratin-Based Hair Fiber Extract to Gold, Keratin, and BMP-2.

Authors:  Roche C de Guzman; Shanel M Tsuda; Minh-Thi N Ton; Xiao Zhang; Alan R Esker; Mark E Van Dyke
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

7.  Optimum conditions of radioligand receptor binding assay of ligands of benzodiazepine receptors.

Authors:  Fatemeh Ahmadi; Sara Dabirian; Mehrdad Faizi; Sayyed Abbas Tabatabai; Davood Beiki; Soraya Shahhosseini
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

Review 8.  Insight into the Development of PET Radiopharmaceuticals for Oncology.

Authors:  Joseph Lau; Etienne Rousseau; Daniel Kwon; Kuo-Shyan Lin; François Bénard; Xiaoyuan Chen
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

9.  Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?

Authors:  Talakad G Lohith; Emily K Osterweil; Masahiro Fujita; Kimberly J Jenko; Mark F Bear; Robert B Innis
Journal:  Mol Autism       Date:  2013-05-24       Impact factor: 7.509

10.  Development of DOTA-Rituximab to be Labeled with 90Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma.

Authors:  Fariba Johari Doha; Siyavash Rahmani; Pedram Rikhtechi; Samira Rasaneh; Zahra Sheikholislam; Soraya Shahhosseini
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.